TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01866306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV16UB
Description: RV16UB is administered by spraying an atomized viral suspension into a single nostril. Planned doses of RV16UB in Part 1 are 10 Tissue Culture Infective Dose 50 (TCID50), 100 TCID50, 1000 TCID50 and 10,000 TCID50.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV16UB
Description: RV16UB is administered by spraying an atomized viral suspension into a single nostril. Planned doses of RV16UB in Part 1 are 10 Tissue Culture Infective Dose 50 (TCID50), 100 TCID50, 1000 TCID50 and 10,000 TCID50.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV16UB
Description: RV16UB is administered by spraying an atomized viral suspension into a single nostril. Planned doses of RV16UB in Part 1 are 10 Tissue Culture Infective Dose 50 (TCID50), 100 TCID50, 1000 TCID50 and 10,000 TCID50.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV16UB
Description: RV16UB is administered by spraying an atomized viral suspension into a single nostril. Planned doses of RV16UB in Part 1 are 10 Tissue Culture Infective Dose 50 (TCID50), 100 TCID50, 1000 TCID50 and 10,000 TCID50.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV16UB
Description: RV16UB is administered by spraying an atomized viral suspension into a single nostril. Planned doses of RV16UB in Part 1 are 10 Tissue Culture Infective Dose 50 (TCID50), 100 TCID50, 1000 TCID50 and 10,000 TCID50.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV16UB
Description: RV16UB is administered by spraying an atomized viral suspension into a single nostril. Planned doses of RV16UB in Part 1 are 10 Tissue Culture Infective Dose 50 (TCID50), 100 TCID50, 1000 TCID50 and 10,000 TCID50.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA
Description: Asthmatic participants were treated with LABA as part of their standard of care
Study: NCT03984097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-079
Description: TAK-079 subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone orally.
Study: NCT01404806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572 (dolutegravir)
Description: Subjects will take an oral daily 50mg dose of GSK1349572 for 5-7 days. GSK1349572 in the CVF and BP will be measured over 24 hours after both the initial dose, and once steady state is reached 5-7 days later at the following time points: 0 (pre-dose) 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24h. Cervical and vaginal biopsies will be collected once at initial dose at either 3, 6, 12 or 24 hours post dose, and again at steady state at the same single time point. Samples will be collected from 2 subjects per time point. BP and CVF samples will be obtained at 48 and 72 hours following the final GSK1349572 dose.
Study: NCT00623766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 10 mg/kg, administered as an intravenous infusion every 3 weeks during induction and every 12 weeks during maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 10 mg/kg, administered as an intravenous infusion every 3 weeks during induction and every 12 weeks during maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid: Betamethasone
Description: Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with betamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid: Dexamethasone
Description: Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid: Fludrocortisone
Description: Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with fludrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid: Hydrocortisone
Description: Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with hydrocortisone
Study: NCT01001988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample for immunogenicity assessment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JE-CV administered in Study JEC02
Description: Participants received a single dose of JE-CV at 12 to 18 months of age in Study JEC02. No vaccination was administered in Study JEC05
Study: NCT01288144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality improvement initiative
Description: In intervention clinics, the LMR will use the existing reminder function to alert providers that a patient has a probable history of gestational diabetes. The provider will then have the opportunity to clarify the subject's history and order appropriate screening testing. Providers will also have access to online reference material regarding GDM follow-up screening and lifestyle interventions.
Study: NCT00912912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: 50 mg capsules once a day (by mouth) for 4 weeks in a row in a 6 week cycle.
Study: NCT00191113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: 0.05 mg/kg/dose by subcutaneous injection 6 times per week, until Core study completion criteria are met (protocol final height).

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Ethinyl estradiol
Description: escalating doses 2.5-20.0 mcg tablets daily after age 13 and at least one year on study, continuing until Core study completion criteria are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol
Description: escalating doses 2.5-20.0 mcg tablets daily after age 13 and at least one year on study, continuing until Core study completion criteria are met.

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Medroxyprogesterone acetate
Description: 10 mg tablets, ten days monthly, after age 15, continuing until Core study completion criteria are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Description: 10 mg tablets, ten days monthly, after age 15, continuing until Core study completion criteria are met.
Study: NCT01181960

Intervention type: DRUG
Intervention: Risperidone long acting injectable - New Starts
Description: Patients who switch to Risperidone long acting injectable or receive an initial injection of Risperidone long acting injectable within the 30 days prior to enrollment will be eligible for inclusion in the Risperidone long acting injectable New Starts cohort.

Intervention type: DRUG
Intervention: Risperidone long acting injectable - Continuous Users
Description: Patients who have been on Risperidone long acting injectable for at least 6 months before baseline, with no gaps between injections of more than 30 days will be eligible for inclusion in the Risperidone long acting injectable Continuous Users cohort.

Intervention type: DRUG
Intervention: Paliperidone Palmitate -New and Continuous Users
Description: Patients newly initiating Paliperidone Palmitate or on Paliperidone Palmitate at the time of enrollment

Intervention type: DRUG
Intervention: Other Antipsychotics - New Starts
Description: Participants in the other antipsychotic cohort may be newly started on any oral or injectable antipsychotic other than Risperidone long acting injectable and Paliperidone Palmitate
Study: NCT01952210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutritional consultation and exercise program
Description: The protocol involved 20-30 minutes of individual-based nutrition consultation every week during the 8-week chemoradiation therapy. The exercise program consisted of upper extremity muscle training and walking exercise at 45%-65% of maximal heart rate reserve, 3 times per week, 20-30 minutes per session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: pre-CCRT education included self-care during CCRT and body weight maintenance
Study: NCT05584592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intergrate early palliatuve care + Conventional chemotherapy
Description: Sixty patients with gastric and pancreatic cancer will be eligible, and 30 patients will be randomly assigned to the exercise therapy + high protein supplement group and 30 patients to the exercise therapy + placebo supplement group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional chemotherapy
Description: patients to receive routine palliative care when they want it or when it is needed by health care providers. In other words, if a patient assigned to the control group desires palliative care, they can receive conventional palliative care.
Study: NCT03984097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib subcutaneously.
Study: NCT00623766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid: Meprednisone
Description: Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with meprednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid: Methylprednisolone
Description: Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid: Prednisolone
Description: Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisolone
Study: NCT03984097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide orally.
Study: NCT04564729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Decision Making
Description: The intervention group will receive a shared decision-making intervention including a decision aid and conversation with a study investigator. The intervention group will have the opportunity to choose the number of opioid pills they receive at discharge from hospital after total knee arthroplasty.
Study: NCT00156104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: 5 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: 10 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: 4 mg BID

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo arm
Study: NCT03880370

Intervention type: BEHAVIORAL
Intervention: Questionnaires / scales
Description: EVA, ROLAND MORRIS, OWESTRY and Global Questionnaire of Physical Activity (GPAQ)

Intervention type: BEHAVIORAL
Intervention: Questionnaires / scales
Description: EVA, ROLAND MORRIS, OWESTRY and Global Questionnaire of Physical Activity (GPAQ)

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound imaging
Description: Rectus abdominis dominant side \& non-dominant side external oblique dominant side \& non-dominant side internal oblique dominant side \& non-dominant side transversus abdominis dominant side \& non-dominant side lumbar multififidus l4-l5-s1 gluteus medius dominant side \& non-dominant side

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound imaging
Description: Rectus abdominis dominant side \& non-dominant side external oblique dominant side \& non-dominant side internal oblique dominant side \& non-dominant side transversus abdominis dominant side \& non-dominant side lumbar multififidus l4-l5-s1 gluteus medius dominant side \& non-dominant side

Intervention type: DIAGNOSTIC_TEST
Intervention: FLEXIBILITY
Description: weight-bearing lunge hip lateral rotation straight leg raise fingertip to floor test

Intervention type: DIAGNOSTIC_TEST
Intervention: FLEXIBILITY
Description: weight-bearing lunge hip lateral rotation straight leg raise fingertip to floor test

Intervention type: DIAGNOSTIC_TEST
Intervention: FUNCTIONAL TESTS
Description: Star excursion balance test (sebt) prone bridging test Side bridging test Modified biering-sørensen

Intervention type: DIAGNOSTIC_TEST
Intervention: FUNCTIONAL TESTS
Description: Star excursion balance test (sebt) prone bridging test Side bridging test Modified biering-sørensen
Study: NCT02097719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost 0.01%
Description: Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: travoprost 0.004%
Description: Travoprost 0.004% administered to both eyes once daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol 0.5%
Description: Timolol 0.5% administered to both eyes once daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hypromellose 0.3%
Description: Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
Study: NCT01039545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Diclofenac retard 75mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norfloxacin
Description: Norfloxacin 400mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
Study: NCT02551380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLINORAL
Description: Folinoral (folinic acid) 5mg twice a day (10 mg per day) during 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 5mg twice a day (10 mg per day) during 12 weeks
Study: NCT01087359

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin
Description: 100 mg melatonin is tested on human endotoxaemia administrated on night and day time compared to placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 100 mg melatonin is tested on human endotoxaemia administrated on night and day time compared to placebo
Study: NCT01943058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: megestrol acetate
Description: Given PO
Study: NCT00440219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Prednisone
Description: Prednisone 50 mg once daily for 10 days pre-op

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo pill identical to Prednisone 10 days once daily pre-op
Study: NCT03233503

Intervention type: DIAGNOSTIC_TEST
Intervention: Basic taste, fat sensation and texture perception
Description: This is an observational Sensory study methodologically similar to Astringency and bitterness perception clinicalTrials.gov identifier NCT03171402 Participants are first involved in sensory training sessions that train how they recognise between different basic tastes and differentiate perceived intensity in solutions and foods. After 6 months of training, the trained participants are involved in tasting a wide array of commonly consumed foods. At this study phase, participants will rate for the foods' taste, fat sensation perception and texture
Study: NCT01943058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: levonorgestrel-releasing intrauterine system
Description: Given IUD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT02933424

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Powder
Study: NCT02933424

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Powder

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Powder
Study: NCT01786044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MasterMed
Description: An online interactive educational program

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Study: NCT01929434

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation
Description: Patients only receive rehabilitation of physical therapy and occupational therapy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stem cell injection
Description: Mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture.
Study: NCT03856164

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Two doses of Tranexamic Acid (1 gram), diluted in 100 cc of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.
Study: NCT00089154

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: apolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00623766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid: Prednisone
Description: Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisone
Study: NCT02202915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Checklist
Study: NCT03657784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277
Description: Single intravenous bolus injection at 0.1 mmol/kg body weight at a rate of 2 mL/second

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277
Description: Single intravenous bolus injection at 0.1 mmol/kg body weight at a rate of 2 mL/second

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277
Description: Single intravenous bolus injection at 0.1 mmol/kg body weight at a rate of 2 mL/second

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277
Description: Single intravenous bolus injection at 0.1 mmol/kg body weight at a rate of 2 mL/second

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277
Description: Single intravenous bolus injection at 0.1 mmol/kg body weight at a rate of 2 mL/second
Study: NCT03909906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Euphytose®
Description: (50mg Valeriana officinalis L., 40mg Passiflora incarnate L., 10mg Crataegus sp., 10mg Ballota nigra L.)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo comparator
Study: NCT04979026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active ankle pumping with a regular watch alarm
Description: In addition to the active ankle pumping exercise for the operative limb, the patients were reminded to exercise at specific time points with a vocal alarm and vibration through a wrist watch during the hospitalization period and at home after discharge.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intermittent pneumatic compression
Description: In this group, intermittent pneumatic compression was applied to the operative low limb during hospitalization, while active ankle pumping exercise was adopted without any reminder after discharge.
Study: NCT02569424

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient's position
Description: Supine or Trendelenburg strict -20°)
Study: NCT03254706

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peak etch-and-rinse (P1)
Description: Application Mode - Peak Adhesive system applied according to the manufacturer's instructions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peak applied for double time(P2X)
Description: Application Mode - Peak Adhesive system applied according to the manufacturer's instructions, but for the double time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single Link etch-and-rinse (SL1)
Description: Application Mode - Single Link Adhesive system applied according to the manufacturer's instructions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single Link double time (SL2X)
Description: Application Mode - Single Link Adhesive system applied according to the manufacturer's instructions, but for the double time.
Study: NCT00623766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid: Triamcinolone
Description: Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with triamcinolone
Study: NCT04202432

Intervention type: DIAGNOSTIC_TEST
Intervention: Mean systemic filling pressure
Description: Peri- and postoperative measurement of continuous cardiac output with thermodilution derived pulse contour calculated device (PiCCO).~Estimation of mean systemic filling pressure using a computerized algorithm and by creating venous return curves with inspiratory hold maneuvers, thereby extrapolating the VR-curve until mean systemic filling pressure is calculated.
Study: NCT02387073

Intervention type: OTHER
Intervention: Electrical version patient reported outcome questionnaire
Description: Assess satisfaction of patients with electrical version patient reported outcome questionnaire.
Study: NCT02159365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide